SOLTI-1804 HER2-PREDICT
Biomarker Program
HER2-PREDICT: Translational study of tumor samples from patients treated with Trastuzumab Deruxtecan (T-DXd; DS-8201a)
Status
Follow-up
Tumour subtype:
HER2+ breast cancer
Scenario
Locally Advanced or Metastatic
SPONSOR
COLLABORATORS
Daiichi Sankyo
PRINCIPAL INVESTIGATORS
Aleix Prat, MD, PhD (Hospital Clínic de Barcelona)
Sites
HOSPITAL CLINIC DE BARCELONA, HOSPITAL DE JEREZ DE LA FRONTERA, HOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, HOSPITAL UNIVERSITARIO DE CANARIAS, HOSPITAL UNIVERSITARIO DE LA PAZ, HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA, HOSPITAL UNIVERSITARIO VIRGEN DE LA MACARENA, HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA, HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, ICO BADALONA, ICO HOSPITALET (DURAN I REYNALS), INSTITUTO VALENCIANO DE ONCOLOGÍA, HOSPITAL DEL MAR
